INVICTUS' ACREAGE PHARMS RECEIVES OIL EXTRACTION LICENSE FROM HEALTH CANADA
August 07 2018 - 10:05AM
InvestorsHub NewsWire
Vancouver, BC -- August 07, 2018 -- InvestorsHub
NewsWire -- INVICTUS MD STRATEGIES CORP. (“Invictus” or the
“Company”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1)
is pleased
to announce that its wholly owned subsidiary, Acreage Pharms Ltd.
("Acreage Pharms"), has received an amended
license from Health Canada, under the Access to Cannabis for
Medical Purposes Regulations (“ACMPR”), to include
the production of bottled cannabis oil and cannabis resin,
effective August 3, 2018.
Acreage Pharms’
state-of-the-art closed-loop CO2 extraction process
produces the highest-quality cannabis oils in the world. The system
performs Subcritical and Supercritical Fluid Extraction utilizing
high-pressure carbon dioxide to extract essential oils from
botanicals, using specific temperatures and pressures to withdraw
different components from plants. Through this extraction process,
CBD and THC levels can be adjusted to ensure a diverse selection
for consumers.
“We are building a
robust portfolio of flower and oil products to satisfy consumer
demand in both the medical and recreational markets,” said Dan
Kriznic, Chairman and CEO of Invictus. “Research shows CBD products
are increasing in popularity, but the market is still unknown. We
need to be able to adjust our product offerings as the market
evolves over time.”
Compared to solvent
extractions, Acreage Pharms Supercritical CO2 extraction
will be:
- Non-Toxic and
Non-Carcinogenic. Oils extracted using CO2 do not
contain petroleum particles.
- Safe. The system does not use potentially flammable
or explosive petroleum-based solvents.
- Carbon-Neutral and Environmentally Friendly. The
system does not emit carbon.
- Customizable. With a wide range of temperatures,
pressures and flow rates to leverage, the system is capable of
withdrawing full profiles of natural compounds found within
cannabis.
- Premium quality. The advanced system is used by top
companies to extract coffee, vanilla, tea, fruit and nuts, omega-3
oils, fragrances, tobacco for e-cigarettes, hop-oil for beer, and
high-grade cannabis oil.
Acreage Pharms’ oil
extraction and quality assurance program will be overseen by
registered Pharmacist and Responsible Person in Charge, Chris
Kooner, supported by a skilled technical team of PHD’s and
experienced cultivators.
For
more information, please visit www.invictus-md.com.
On Behalf of the Board,
Dan
Kriznic
Chairman and CEO
Jessica
Martin
Vice
President, Public Relations and Regulatory
Affairs
(647)
828-9655
About Invictus
Invictus is a global
cannabis company offering a selection of products under a wide
range of lifestyle brands. Our integrated sales approach is defined
by five pillars of distribution including medical, wholesale,
international, Licensed Producer to Licensed Producer and
retail.
Invictus has partnered
with business leaders to convey our corporate vision, including
KISS music legend and business mogul Gene Simmons as our Chief
Evangelist Officer, and global branding agency Authentic Brands
Group. Invictus is expanding its cultivation footprint, with two
cannabis production facilities fully licensed under ACMPR in Canada
and a third awaiting approval, featuring 100,000 square feet of
available grow space today with 200,000 expected by the end of 2018
and 1 million by end of 2019. The Company will earmark 50 per cent
of production to the medical and recreational markets,
respectively. To ensure consistency in quality and supply, Invictus
maintains all aspects of the growing process through its
subsidiary, Future Harvest Development Ltd., a high-quality
Fertilizer and Nutrients manufacturer. Invictus drives sustainable long-term
shareholder value through a diversified product portfolio with over
69 Health Canada approved strains and a multifaceted distribution
strategy including medial, recreational, international and retail.
For more information visit www.invictus-md.com.
Cautionary Note Regarding Forward-Looking
Statements: This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian securities laws or
forward-looking statements within the meaning of the United States
Private Securities Litigation Reform Act of 1995. All statements in
this news release, other than statements of historical facts,
including statements regarding future estimates, plans, objectives,
timing, assumptions or expectations of future performance,
including the potential acquisition of OptionCo pursuant to the
exercise of the Option, and the potential production capacity of
OptionCo, AB Labs, AB Ventures and Acreage Pharms, are
forward-looking statements and contain forward-looking information.
Generally, forward-looking statements and information can be
identified by the use of forward-looking terminology such as
“intends” or “anticipates”, or variations of such words and phrases
or statements that certain actions, events or results “may”,
“could”, “should”, “would” or “occur”. Forward-looking statements
are based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release, including that the Company will be
successful in exercising the Option and obtaining TSX Venture
Exchange approval of the acquisition, that OptionCo and AB Labs
will be successful in reaching their potential production capacity,
OptionCo, AB Ventures and Acreage Pharms’ production facilities
will be completed as anticipated, regulatory approval will be
granted as anticipated, OptionCo and AB Labs will reach full
production capacity on the timeline anticipated by the Company,
OptionCo will be granted its first and second licenses, AB Labs
will be granted its secondary license on the terms and timeline
anticipated by the Company, no unforeseen construction delays will
be experienced, and OptionCo and Acreage Pharms will be granted its
sales license under the ACMPR on the terms and timeline anticipated
by the Company,. These forward-looking statements are subject
to known and unknown risks, uncertainties and other factors that
may cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, the
Company will not complete the acquisition of OptionCo, OptionCo and
AB Labs will not be successful in reaching its potential production
capacity, OptionCo, AB Ventures and Acreage Pharms’ production
facilities will not be completed as anticipated, construction
delays, regulatory approval will not be granted as anticipated and
therefore, the anticipated timing of OptionCo and AB Labs reaching
full production capacity will be delayed, AB Labs will not be
granted their secondary license, OptionCo will not be granted
its first and second licenses and OptionCo and Acreage Pharms will
not be granted its sales license under the ACMPR, and licenses or
approvals being granted on terms or timelines that are materially
worse than expected by the Company. Although management of
the Company has attempted to identify important factors that could
cause actual results to differ materially from those contained in
forward-looking statements or forward-looking information, there
may be other factors that cause results not to be as anticipated,
estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements and forward-looking information. Readers
are cautioned that reliance on such information may not be
appropriate for other purposes. The Company does not undertake to
update any forward-looking statement, forward-looking information
or financial out-look that are incorporated by reference herein,
except in accordance with applicable securities
laws.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024